uniQure NV (LTS:0EE0) Float Percentage Of Total Shares Outstanding: 98.67% (As of Jul. 08, 2026)


LTS:0EE0 uniQure NV LTS:0EE0
47 GF Score
Price $42.90
GF Value $5.97
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV Float Percentage Of Total Shares Outstanding?

uniQure NV LTS:0EE0 +4.24% 47 Float Percentage Of Total Shares Outstanding is 98.67% as of Jul. 08, 2026. GuruFocus rates LTS:0EE0 with a GF Score™ of 47/100 and a GF Value™ of $5.97 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, uniQure NV's float shares is 67.83 Mil. uniQure NV's total shares outstanding is 68.75 Mil. uniQure NV's float percentage of total shares outstanding is 98.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, uniQure NV's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, uniQure NV's Institutional Ownership is 24.27%.

LTS:0EE0
47GF Score
uniQure NV LTS:0EE0
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

uniQure NV Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

uniQure NV's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=67.83/68.75
=98.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 98.67% mean?
uniQure NV (LTS:0EE0) has a Float Percentage Of Total Shares Outstanding of 98.67% as of Jul. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on uniQure NV and its competitors.
Is uniQure NV's Float Percentage Of Total Shares Outstanding too high?
uniQure NV's current Float Percentage Of Total Shares Outstanding is 98.67%. Overall, uniQure NV has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Float Percentage Of Total Shares Outstanding compare to ALMS and ARQT?
uniQure NV's Float Percentage Of Total Shares Outstanding of 98.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on uniQure NV and its competitors. uniQure NV's current Float Percentage Of Total Shares Outstanding is 98.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (LTS:0EE0) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.97, compared to a current price of $42.90 — trading 618.6% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 98.67%. uniQure NV's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For uniQure NV (LTS:0EE0), the current Float Percentage Of Total Shares Outstanding is 98.67% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (LTS:0EE0) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of $42.90 is trading 618.6% above its estimated GF Value™ of $5.97. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for LTS:0EE0:

  • Float Percentage Of Total Shares Outstanding: 98.67%
  • GF Value™: $5.97 vs. price of $42.90 (618.6% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the LTS:0EE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
47GF Score

Get the complete analysis for LTS:0EE0

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.90
Price
$5.97
GF Value